Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 120

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 120
---
 planned synchrony with the newly formed cartilage tissue.

<div align='center'>70</div>

Mode of Action of GelrinC:

| 1. Stelar delivery device membrane covers cartilage lesion. Using a syringe GelrinC is introduced into the lesion.                                                     |     | 2. Upon filing of the lesion, UV beam cures GelrinC into a soft rubbery implant.                                            |
| 3. As GelrinC implant recedes and resorbs, the cartilage lesion rim creates aggregates and new cartilage tissue filling up the void created by the retreating implant. |     | 4. At the end of 6-9 months with functioning knee, GelrinC implant is resorbed and new cartilage covers the treated lesion. |

<div align='center'>71</div>

As demonstrated in the Pilot
Study, the advantages of GelrinC include:

| ● | An off-the-shelf product for cartilage repair; |

| ● | A new class of a-cellular product solution; |

| ● | Polyethylene glycol, or PEG, implant preventing cellular migration as a primary mode of action and further aided by denatured fibrinogen controlled erosion for the regeneration of hyaline-like cartilage; |

| ● | Initial state as liquid form provides for complete and optimal defect filling and subsequent curing hardens it into a more solid body, and holding it in place; |

| ● | Single, 10 minutes surgical procedure; |

| ● | Implantable via open or minimally-invasive surgical techniques; |

| ● | Manufacturing process allows for low cost of goods and scalability; and |

| ● | Intended for the repair of focal defects in cartilage and/or osteochondral defects. |

All of these advantages were
demonstrated in the Pilot Study where the recovery of the patient took approximately two weeks of non-weight bearing activity, and led
to a full recovery within three to six months. Additionally, 100% of the participants who were followed up with in the Pilot study reported
no pain in their recovery through at least four years thereafter.

Future Products; Additional Applications

Based on similarity of mechanism
of action for cartilage and based on animal studies performed by the Company for osteoarthritis, we believe that in the future, our Gelrin
technology platform may also provide a solution to osteoarthritis and other cartilage injuries related to the ankle, wrist, and elbow.

| ● | GelrinP